InsidersTradesSigma
Follow the STOKE THERAPEUTICS INC share price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2bn. The latest transaction was reported on 1 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: BARUCH S. TICHO. The full history is openly available.
Analysts rate STOKE THERAPEUTICS INC Strong Buy (bullish), based on 13 analysts. Average price target: US$46.46.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
STOKE THERAPEUTICS INC is a biopharmaceutical company focused on developing therapies to treat genetic diseases. It employs an innovative approach to modulate gene expression to correct genetic defects.